Methods and compositions for immunoregulation
AssigneeTrillium Therapeutics Inc.
InventorsReginal M. Gorczynski, David A. Clark
Life of this patent
Estimating the term…
Abstract
Methods and compositions for inducing immune suppression are disclosed. The methods involve administering an effective amount of an agent that inhibits MD-1 with or without an OX-2 protein or a nucleic acid encoding an OX-2 protein. The methods are useful in preventing graft rejection, fetal loss, autoimmune disease, and allergies. Methods and compositions for preventing immune suppression are also disclosed. The methods involve administering an effective amount of MD-1 or an agent that activates or stimulates MD-1.
Claims21
A use of an inhibitor of MD-1 to prepare a medicament to suppress an immune response.
A use of an MD-1 protein or a nucleic acid sequence encoding an MD-1 protein to prepare a medicament to enhance an immune response.
A use of an MD-1 protein or a nucleic acid sequence encoding an MD-1 protein to prepare a medicament to induce fetal loss.
A pharmaceutical composition for use in suppressing an immune response comprising an inhibitor of MD-1 in admixture with a suitable diluent or carrier.
A pharmaceutical composition for use in preventing immune suppression comprising an MD-1 protein or a nucleic acid encoding an MD-1 protein in admixture with a suitable diluent or carrier.
A method of identifying substances which can bind with MD-1, comprising the steps of:
- (a) reacting MD-1 and a test substance, under conditions which allow for formation of a complex between the MD-1 and the test substance, and
- (b) assaying for complexes of MD-1 and the test substance, for free substance or for non complexed MD-1, wherein the presence of complexes indicates that the test substance is capable of binding MD-1.
A method for identifying a compound that affects the binding of an MD-1 protein and an MD-1 binding protein comprising:
- (a) incubating (i) a test compound;
- (ii) an MD-1 protein and (iii) an MD-1 binding protein under conditions which permit the binding of MD-1 protein to the MD-1 binding protein;
- and
- (b) assaying for complexes of MD-1 protein and the MD-1 binding protein and comparing to a control, wherein a reduction of complexes indicates that the compound has an effect on the binding of the MD-1 protein to an MD-1 binding protein.
Dependencies are inferred from the claim text.